It is a novel selective melanocortin 2 receptor (MC2R) antagonist for rare metabolic disorders such as congenital adrenal hyperplasia.

What is the scale of the license agreement?

We receive a one-time payment of 20 million US dollars, and up to 550 million US dollars in milestones based on development progress.

What kind of company is Scophia Pharma?

It is a Japanese biotech company focused on developing new drugs to address unmet medical needs, particularly in endocrine and metabolic areas.

AI News NQ Analysis

Regarding the Execution of a Global Exclusive License Agreement with Neurocrine Biosciences for Selective MC2R Antagonist SCO-483

NQ Score 82/100

N1 Content Completeness 9

AI Summary (NQ-processed)

Scohia Pharma entered into a global exclusive license agreement with Neurocrine Switzerland GmbH for SCO-483, a novel MC2R antagonist. Scohia will receive a $20M upfront payment and up to $550M in milestones.

AI Analysis

Frequently Asked Questions

Q: What is SCO-483?: A: It is a novel selective melanocortin 2 receptor (MC2R) antagonist for rare metabolic disorders such as congenital adrenal hyperplasia.
Q: What is the scale of the license agreement?: A: We receive a one-time payment of 20 million US dollars, and up to 550 million US dollars in milestones based on development progress.
Q: What kind of company is Scophia Pharma?: A: It is a Japanese biotech company focused on developing new drugs to address unmet medical needs, particularly in endocrine and metabolic areas.